The Alopecia Areata Consensus of Experts (ACE) Study PART II: Results of an International Expert Opinion on Diagnosis and Laboratory Evaluation for Alopecia Areata

Nekma Meah, MBChB, MRCP (UK), FACD, Dmitri Wall, MBCh, BAO, MRCP, Katherine York, MBCh, FC Derm (SA), Bevin Bhoyrul, MBBS, MRCP (UK), Laita Bokhari, MPhil Med, Daniel Asz Sigall, MD, Wilma F. Bergfeld, MD, Regina C. Betz, MD, Ulrike Blume-Peytavi, MD, Valerie Callender, MD, FAAD, Vijaya Chitreddy, FACD, Andrea Combalia, MD, George Cotsarelis, MD, Brittany Craiglow, MD, Jeff Donovan, MD, PhD, Samantha Eisman, MBChB, MRCP, FACD, Paul Farrant, MBBS, BSc, MRCP, Jack Green, FACD, Ramon Grimalt, MD, PhD, Matthew Harries, PhD, FRCP, Maria Hordinsky, MD, FAAD, Alan D. Irvine, MD DSc, Satoshi Itami, MD, PhD, Victoria Jolliffe, MA(Cantab), FRCP, FRCS(Ed), MRCGP, SFHEA, Brett King, MD, PhD, Won-Soo Lee, MD, PhD, Amy McMichael, MD, Andrew Messenger, MD, FRCP, Paradi Mirmirani, MD, Elise Olsen, MD, Seth J. Orlow, MD, PhD, Bianca Maria Piraccini, MD, PhD, Adriana Rakowska, MD, Pascal Reygagne, MD, Janet L. Roberts, MD, FAAD, Lidia Rudnicka, MD, PhD, Jerry Shapiro, MD, FAAD, Pooja Sharma, MBBS, FACD, Antonella Tosti, MD, Annika Vogt, MD, Martin Wade, FACD, Leona Yip, MBChB, PhD, FACD, Abraham Zlotogorski, MD, Rodney D. Sinclair, MBBS, MD, FACD

PII: S0190-9622(20)32614-1
DOI: https://doi.org/10.1016/j.jaad.2020.09.028
Reference: YMJD 15219

To appear in: Journal of the American Academy of Dermatology

Received Date: 29 July 2020
Revised Date: 3 September 2020
Accepted Date: 4 September 2020


This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2020 Published by Elsevier on behalf of the American Academy of Dermatology, Inc.
TITLE PAGE

**Journal:** Journal of the American Academy of Dermatology

**Article type:** Original article

**Title:** The Alopecia Areata Consensus of Experts (ACE) Study PART II: Results of an International Expert Opinion on Diagnosis and Laboratory Evaluation for Alopecia Areata

**Authors:**

*Nekma Meah*

MBChB, MRCP (UK), FACP

ORCID ID: 0000-0001-9466-6337

Sinclair Dermatology 2 Wellington Parade, East Melbourne, Victoria 3002, Australia

COI: None

*Dmitri Wall*¹,²

MBChB, BAO, MRCP

ORCID ID: 0000-0002-0107-4488

¹. Hair Restoration Blackrock; 2. National and International Skin Registry Solutions (NISR), Ireland

COI: Dr Wall has received personal fees (honoraria) from Janssen, (consultancy fees) Eli-Lilly and non-financial support (travel fees/grant) from Pfizer. Dr Wall has received personal fees for consultancy from the not-for-profit company, National and International Skin Registry Solutions (NISR).
Katherine York
MBBCh, FCDerm (SA)
ORCID ID: 0000-0003-2905-4494
Netcare Greenacres hospital, Port Elizabeth, South Africa
COI: None

Bevin Bhoyrul
MBBS, MRCP (UK)
ORCID ID: 0000-0002-1123-6882
Sinclair Dermatology 2 Wellington Parade, East Melbourne, Victoria 3002, Australia
COI: None

Laita Bokhari
MPhil Med
ORCID ID: 0000-0003-4522-2611
Sinclair Dermatology 2 Wellington Parade, East Melbourne, Victoria 3002, Australia
COI: None
Daniel Asz Sigall

MD

ORCID ID: 0000-0003-1848-5686

Dermalomas Clinic, Mexico City, Mexico

COI: None

Wilma F. Bergfeld

MD

ORCID ID:

Cleveland Clinic Main Campus, 9500 Euclid Avenue, Cleveland, OH 44195, USA

COI:

Regina C. Betz

MD

ORCID ID: 0000-0001-5024-3623

Institute of Human Genetics, University of Bonn, School of Medicine & University Hospital

Bonn, Bonn, Germany

COI: None
Ulrike Blume-Peytavi

MD

ORCID ID: 0000-0003-3528-3752

Department of Dermatology, Venerology and Allergology, Clinical Research Center for Hair and Skin Science, Charité-Universitätsmedizin Berlin, Berlin Germany

COI: has received Honoraria and Consultancies from Abbvie, Bayer, Galderma, Pfizer, Pierre Fabre Dermocosmetics, Sanofi and Regeneron, none relevant to this work.

Valerie Callender

MD, FAAD

ORCID ID:

Callender Dermatology & Cosmetic Center, Glenn Dale, Maryland, USA

COI: Principal Investigator for Lilly Clinical Trial

Vijaya Chitreddy

FACD

ORCID ID: 0000-0002-0273-9592

Sinclair Dermatology 2 Wellington Parade, East Melbourne, Victoria 3002, Australia

COI: None
Andrea Combalia

MD

ORCID ID: 0000-0003-0583-9000

Department of Dermatology, Hospital Clinic de Barcelona, Barcelona, Spain

COI: None

George Cotsarelis

MD

ORCID ID:

Department of Dermatology University of Pennsylvania School of Medicine Philadelphia,
Pennsylvania 19104 USA

COI: Co-investigator in a clinical trial sponsored by Lilly

Brittany Craiglow

MD

ORCID ID: 0000-0001-8970-7691

Dermatology Physicians of Connecticut, Farifield, Connecticut & Yale Department of Dermatology,
New Haven, Connecticut ,USA

COI: has received honoraria and/or fees from Aclaris, Arena Pharmaceuticals, Pfizer, Regeneron & Sanofi-Genzyme
Jeff Donovan
MD, PhD
ORCID ID: 0000-0002-8623-2974
Donovan Hair Clinic, 4370 Lorimer Road - Suite 334B Whistler, BCV8E 1A6, Canada
COI: None

Samantha Eisman
MBChB, MRCP, FACD
ORCID ID: 0000-0003-0111-6403
Sinclair Dermatology 2 Wellington Parade, East Melbourne, Victoria 3002, Australia
COI: Dr Samantha Eisman has been principal investigator in clinical trials for Pfizer Inc., AbbVie, Arena Pharmaceuticals, Boston Pharmaceuticals, Bristol-Myers Squibb, Botanix, Dermira, Eli Lilly, LEO Pharma, Novartis, and Regeneron.

Paul Farrant
ORCID ID: 0000-0001-9695-0884
MBBS, BSc, MRCP
Brighton and Sussex University Hospitals Trust, United Kingdom
COI: Consultant for lilly, Principle Investigator for Pfizer in clinical research studies
Jack Green
FACD
ORCID ID: 0000-0002-9698-7334
Department of Dermatology, St.Vincent’s Hospital, Victoria, Australia
COI: None

Ramon Grimalt
MD, PhD
ORCID ID: 0000-0001-7204-8626
Facultat de Medicina i Ciències de la Salut. Universitat Internacional de Catalunya Josep Trueta s/n
08195 Sant Cugat del Vallès (Barcelona), Spain
COI: None

Matthew Harries
PhD, FRCP
ORCID ID: 0000-0002-0563-8690
Centre for Dermatology Research, University of Manchester, MAHSC and NIHR Manchester
Biomedical Research Centre, Manchester, UK
The Dermatology Centre, Salford Royal NHS Foundation Trust, Salford, Manchester, UK
COI: None
Maria Hordinsky

MD, FAAD

ORCID ID:

Professor and Chair, Department of Dermatology, University of Minnesota Medical School, 420 Delaware St SE MMC 98, 4-240 PWB, Minneapolis, MN 55455, USA

COI:

Alan D. Irvine

MD DSc

ORCID ID: 0000-0002-9048-2044

Clinical Medicine, Trinity College Dublin, Ireland

COI: Alan D. Irvine, has received Honoraria and Consultancies from Pfizer, Novartis, Abbvie, Sanofi, Regeneron, none relevant to this work

Satoshi Itami

MD, PhD

ORCID ID:

Department of Dermatology, Oita University 1-1, Iidaigaoka, Yufu City, Oita, 879-5593, Japan

COI: None
Victoria Jolliffe

MA(Cantab), FRCP, FRCS(Ed), MRCGP, SFHEA

Professor of Postgraduate Medical Education and Honorary Consultant Dermatologist, Centre for Cell Biology and Cutaneous Research, Blizard Institute, 4 Newark Street, London E1 2AT, UK

ORCID ID: 0000-0002-1255-3812

COI: None

Brett King

MD, PhD

ORCID ID: 0000-0002-4576-4616

Yale School of Medicine; New Haven, Connecticut, USA

COI: is an investigator for Concert Pharmaceuticals Inc, Eli Lilly and Company, and Pfizer Inc. He is a consultant to and/or has served on advisory boards for Aclaris Therapeutics, Arena Pharmaceuticals, Bristol-Meyers Squibb, Concert Pharmaceuticals Inc, Dermavant Sciences, Eli Lilly and Company, and Pfizer Inc; he is on speaker’s bureau for Pfizer Inc, Regeneron and Sanofi Genzyme.

Won-Soo Lee

MD, PhD

ORCID ID: 0000-0001-7198-1334

Department of Dermatology Yonsei University Wonju College of Medicine, Wonju, Republic of Korea

COI: None
Amy McMichael
MD
ORCID ID: 0000-0002-5342-2181
Wake Forest University School of Medicine, Winston-Salem, NC, USA
COI: has received personal fees for consultancy work with Bioniz, Pfizer and Revian, in addition to personal fees and grants from Aclaris, Concert, Galderma, Allergan, Almirall, Cassiopea, Incyte, Procter and Gamble, and Revian.

Andrew Messenger
MD, FRCP
ORCID ID: 0000-0003-1424-8069
Dept of Infection, Immunity & Cardiovascular Disease, University of Sheffield, United Kingdom
COI: Consultancies with Pfizer and Manentia

Paradi Mirmirani
MD
ORCID ID: 0000-0001-8627-2995
Kaiser Permanente Vallejo, Department of Dermatology, California, USA
COI: has been an investigator for Concert Pharmaceuticals, Pfizer and Eli Lilly
Elise Olsen
MD
ORCID ID:
Duke Dermatology Clinic - Clinic 3K, 40 Duke Medicine Cir, Durham, NC 27710-4000, USA
COI: Aclaris investigator, Arena consultant

Seth J. Orlow
MD, PhD
ORCID ID: 0000-0003-2548-7380
The Ronald O. Perelman Department of Dermatology at NYU Grossman School of Medicine, New York, USA
COI: None

Bianca Maria Piraccini
MD, PhD
ORCID ID: 0000-0001-6537-9689
Deputy for International Relations, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Alma Mater Studiorum University of Bologna, Dermatology Unit, Italy
COI: None
Adriana Rakowska
MD
ORCID ID: 0000-0002-8308-1023
Department of Dermatology, Medical University of Warsaw, Warsaw, Poland
COI: None

Pascal Reygagne
MD
ORCID ID: 0000-0002-6062-2122
Director of Centre de santé Sabouraud, Hôpital Saint Louis, Paris
COI: None

Janet L Roberts
MD, FAAD
ORCID ID: 0000-0003-4843-7108
Northwest Dermatology Institute Portland, OR 97210, USA
COI: None
Lidia Rudnicka

MD, PhD

ORCID ID: 0000-0002-8308-1023

Department of Dermatology, Medical University of Warsaw, Poland

COI: None

Jerry Shapiro

MD, FAAD

ORCID ID:

The Ronald O. Perelman Department of Dermatology New York University School of Medicine 530 First Ave., 7R New York, New York 10016, USA


Pooja Sharma

MBBS, FACD

ORCID ID: 0000-0001-5070-3722

Sinclair Dermatology 2 Wellington Parade, East Melbourne, Victoria 3002, Australia

COI: Pfizer (Sub Investigator), Lilly (Sub investigator).
Antonella Tosti
MD
ORCID ID: 0000-0001-5516-4043
Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery University of Miami Miller School of Medicine, USA
COI: Consultant DS Laboratories, Monat Global, Almirall, Tirthy Madison, Lilly, Leo Pharmaceuticals, Bristol Myers Squibb, P&G.

Annika Vogt
MD
ORCID ID:
Department of Dermatology, Venerology and Allergology, Clinical Research Center for Hair and Skin Science, Charité-Universitätsmedizin Berlin, Berlin Germany
COI: None

Martin Wade
FACD
ORCID ID: 0000-0003-0376-448X
The London Skin and Hair Clinic 233 High Holborn London WC1V 7DN United Kingdom
COI: None
Leona Yip
MBChB, PhD, FACD
ORCID ID: 0000-0001-7120-6610
Skin Partners Specialist Dermatologists, Brisbane, Australia
COI: None

Abraham Zlotogorski
MD
ORCID ID: 0000-0003-4818-3785
Department of Dermatology, Hadassah Medical Center, Hebrew University of Jerusalem, The Faculty of Medicine, Jerusalem, Israel
COI: None

Rodney D Sinclair
MBBS, MD, FACD
ORCID ID: Sinclair Dermatology 2 Wellington Parade, East Melbourne, Victoria 3002, Australia
COI: Dr Rodney Sinclair has served as a consultant or paid speaker for, or participated in clinical trials sponsored by, Leo Pharma, Amgen, Novartis, Merck & Co., Celgene, Coherus Biosciences, Janssen, Regeneron, MedImmune, GlaxoSmithKline, Cutanea, Samson Clinical, Boehringer Ingelheim, Pfizer, MSD, Oncobiologics, Roche, Eli Lilly and Bayer.
Corresponding author:

Dr Nekma Meah
Sinclair Dermatology
2 Wellington Parade,
East Melbourne,
Victoria 3002,
Australia
Nekma.meah@gmail.com

Acknowledgement:

Regina C. Betz is funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under the auspices of the Germany Excellence Strategy – EXC2151 – 390873048.
Matthew Harries is supported by the NIHR Manchester Biomedical Research Centre.
Funding sources: This research has been supported in part by an educational grant from The Australasian Hair and Wool Research Society.
ABSTRACT

Background: We previously reported The Alopecia Areata Consensus of Experts (ACE) Study: Results of an International Expert Opinion on Treatments for Alopecia Areata (AA).

Objective: To report the results of the ACE international expert opinion on diagnosis and laboratory evaluation for AA.

Methods: Fifty hair experts from 5 continents were invited to participate in a 3 round Delphi process. Consensus threshold was set at ≥66%.

Results: Of 148 questions, expert consensus was achieved in 82 (55%) questions. Following round 1 consensus was achieved in 10 of 148 (7%) questions. Round 2 achieved consensus in 47 of 77 questions (61%). The final face-to-face achieved consensus in 25 of 32 (78%) questions. Consensus was greatest for laboratory evaluation (12 of 14 (86%) questions), followed by diagnosis (11 of 14 (79%) questions) of AA. Overall, etiopathogenesis achieved the least category consensus (31 of 68 (46%) questions).

Limitations: The study had low representation from Africa, South America and Asia.

Conclusion: There is expert consensus on aspects of epidemiology, etiopathogenesis, clinical features, diagnosis, laboratory evaluation and prognostic indicators of AA. The study also highlights areas where future clinical research could be directed to address unresolved hypotheses in AA patient care.
CAPSULE SUMMARY

1. This is the first large scale international consensus on the diagnosis and laboratory evaluation of AA.

2. The consensus document identifies potential areas where research may be directed.
INTRODUCTION
We previously reported the first part of The Alopecia Areata Consensus of Experts (ACE) Study. In ACE Part II we present international expert consensus on the pathogenesis, diagnosis and laboratory evaluation of alopecia areata (AA).

Treatment is influenced by a greater understanding of the pathogenesis of AA. ACE Part II bridges theory to clinical practice. It considers the frequently posed questions by AA patients and indeed the general dermatologist. It aims to address the nuances often encountered in practice and be clinically relevant for the treating clinician.

There remain many aspects of AA where the available data is inconclusive. Consensus is defined by a general agreement among members of our expert panel, each of whom has exercised discretion in their decision-making. For questions where the threshold for consensus is achieved, few or none achieve unanimous agreement of the experts and until conclusive data emerges, there will remain divergence of opinion. However, when taken together with current AA guidelines, ACE Part II provides additional insight into the current opinion from hair experts recognized in the field of AA.
METHODS

Expert Panel Selection

Fifty dermatologists with recognized expertise in hair and scalp disorders were invited to participate. Wide international representation was reflected in involvement from all five continents.

Delphi survey

The primary questionnaire was designed by a panel of four dermatologists. A systematic literature review was conducted to formulate questions to cover: epidemiology, etiopathogenesis, diagnosis, laboratory evaluation, treatment and prognosis of AA. Importantly, questions specifically included topics of clinical relevance; patient directed questions (e.g. those encountered in patient consultations); and some esoteric concepts.

The Delphi questionnaire was distributed using an online e-management survey system, Delphi Manager, maintained by the COMET (Core Outcome Measures for Effectiveness Trials) Initiative.

Delphi process

The Delphi process has been validated in numerous studies to determine core outcomes and define diagnostic criteria. It was selected for ACE as it aims to achieve convergence of opinion through a series of rounds. Submitted answers are anonymized to minimise bias, whilst sequential iterations enable revision of judgement based on peer review to achieve consensus, where possible.

ACE involved two questionnaire rounds followed by a final face-to-face meeting (Figure 1). For each questionnaire round, participants were instructed to assign a score for each question from 1-9 or “unable to score”. A score of 1 corresponded to strong disagreement and 9 indicated strong agreement.
Consensus threshold

Threshold values have varied across Delphi studies. Consensus threshold for ACE was set at ≥66% agreement (scores 7-9) or disagreement (scores 1-3) of the participants scoring a given question or statement at round 1, round 2 or the face-to-face meeting but did not necessarily represent consensus of all 50 participants.

Questions with scores 4-6 were regarded as indeterminate. Questions excluded from the next round included those which had achieved consensus (≥66%) and those with a lack of consensus (≤33%), given the low probability that these would achieve consensus.

Questions included in the next round included those with consensus values between 33% and 66%.

Statistical analysis

R version 3.5.3 statistical software package was used for data analysis.
RESULTS

Expert Panel

Of 50 invited hair experts, 41 (82%) completed round 1, 39 (78%) round 2 and 30 (60%) attended the face-to-face meeting at the 11th World Congress for Hair Research (WCHR) in Sitges, Spain. Thirty-six (88%) experts, routinely managed adults and children with hair loss disorders. Twenty-three (56%) work in public (academic institutions) and private practice, 13 (32%) exclusively in private, and 5 (12%) exclusively in public practice. Participants were from Europe (15; 37%); Asia (3; 7%), Australia (9; 22%) and North America (14; 34%).

Delphi rounds

Figure 2 summarizes the ACE Delphi rounds. 148 questions related to epidemiology, etiopathogenesis, clinical features, diagnosis, laboratory evaluation, prognosis and prognostic indicators. Expert consensus was achieved in 82 questions (55%), including 10, 47 and 25 questions following rounds 1, 2 and 3 respectively. The category with the greatest consensus was laboratory evaluation (12 of 14 (86%) questions), followed by diagnosis (11 of 14 (79%) questions). The least consensus achieved was for etiopathogenesis (31 of 68 (46%) questions).

CONSENSUS OUTCOME

1.0 Epidemiology

Six questions related to epidemiology. Consensus was achieved in 3 questions (50%).

- Ethnicity (race) does not alter the natural history/prognosis of AA.
- Neither ethnicity nor climate/geographical latitude influences the risk of a poor response to treatment.
2.0 Etiopathogenesis

Sixty-eight questions related to etiopathogenesis, subdivided into; family history, genetics, autoimmune disease, allergic comorbidities, associated comorbidities, nutritional, stress, and environmental. Consensus was achieved in 31 questions (46%).

- **Factors that were considered to increase the risk of developing AA** include: a family history of AA/organ specific autoimmune disease; genotype; a personal history of autoimmune disease/thyroid disease/vitiligo/atopy or atopic dermatitis. Iron deficiency and pregnancy were not considered to increase the risk of developing AA.

- **Factors that were considered to influence the natural history/prognosis of AA** include genotype; a personal history of autoimmune disease or atopy. Iron deficiency and vaccination were not considered to influence the natural history/prognosis of AA.

- **Factors that were considered to trigger initial disease and episodic relapse(s)** include genotype with environmental trigger; major traumatic life event; acute stress.

- **Factors that were considered to influence the response to treatment** include genotype. Iron deficiency and vaccination were not considered to influence the response to treatment.

3.0 Clinical Features

Consensus was achieved in 11 (48%) of 23 questions regarding clinical features:

- **Signs indicating disease activity** include: exclamation mark hairs; trichoscopic black dots; a positive hair pull test; anagen effluvium.

- **Severity of Alopecia Tool Score (SALT) + Quality of life (QoL)** (e.g. Dermatology Life Quality Index (DLQI)) or SALT + Scalp Surface Area (SSA) + QoL are required in clinical trials involving adults or children.

- **SALT is a sufficient measure of disease extent** in clinical practice in adults and children.
4.0 Diagnosis

Consensus was achieved in 11 (79%) of 14 questions relating to the diagnosis of AA:

- AA diagnosis can be determined by clinical examination and trichoscopic findings.
- Hair pluck trichograms are not useful in the diagnosis of AA.
- Scalp biopsy is indicated in the following circumstances: a solitary patch recalcitrant to treatment; diffuse alopecia; and when cicatricial alopecia cannot be excluded clinically.
- When performing scalp biopsies in AA, it is usually sufficient to take one single biopsy (for horizontal and vertical sectioning) to confirm the diagnosis of AA, but occasionally two or more biopsies (for horizontal and vertical sectioning) may be needed.
- Biopsy site should be from the edge of a lesion (not the center), and preferably from a lesion located at a site normally resistant to androgenetic alopecia (e.g. occipital scalp).
- An additional scalp biopsy from non-lesional scalp is not considered important.

5.0 laboratory evaluation

Consensus was achieved in 12 (86%) of 14 statements regarding laboratory evaluation of AA:

- Fungal microscopy should not be performed routinely and is only required when there is clinical suspicion of tinea capitis.
- Routine blood tests (full blood count, renal and liver function) and screening for autoimmune disease, connective tissue disease, celiac disease, pernicious anemia and diabetes are not required and should not be performed in all patients at the time of diagnosis of AA.
- In the absence of relevant clinical symptoms and signs, viral serology is not useful to identify a potential AA episode trigger.
• Early morning cortisol is not a useful test in patients who believe stress may have triggered an AA episode.

• Prior to initiation of systemic treatment of AA, investigation is identical to requirements for other dermatological diseases.

6.0 Prognosis and Prognostic indicators

The effect of disease duration and disease phenotype on AA progression was addressed. Poor prognosis in this context referred to developing a severe disease phenotype but did not imply refractory to treatment; and response to treatment was queried separately. Consensus was achieved in 14 (61%) of 23 questions.

• Prognosis is worse when AA persists beyond 5 years.

• Hair loss can become irreversible when AA persists for 10 years but should not be assumed to be so or contraindicate a trial of therapy.

• Development of lesions of alopecia can be influenced by systemic factors e.g. metabolic (hormones) and immunological (proinflammatory cytokines) factors.

• Ophiasis phenotype indicates poor prognosis.

• Eyebrow, eyelash and non-scalp hair loss indicates poor prognosis.

• Nail pitting suggests an increased risk of developing AT/AU, worsens AA prognosis and reduces response to treatment.

• Trachyonychia suggests an increased risk of developing AT/AU and worsens AA prognosis.

NON-CONSENSUS OUTCOME

Table 1 summarizes non consensus outcomes. Consensus was not achieved in 66 questions (45%); 61, 0 and 5 questions following rounds 1, 2 and 3, respectively.
DISCUSSION

ACE Part II represents the largest international expert consensus study on the diagnosis and laboratory evaluation for AA achieved via the Delphi process.

Consensus was achieved for genotype increasing the risk of developing AA, affecting the prognosis of AA and influencing the response to treatment of AA. AA is considered a complex polygenic disorder and the genetic aetiology is well described. A positive family history is reported in 20-40% of cases and twin studies have shown high concordance (42%) among monozygotic twins. The first AA genome-wide association study (GWAS) identified eight regions in the genome associated with AA, increasing to 14 susceptibility loci in later studies.

Acute stress was recognized as a trigger for initial disease and episodic relapse(s) of AA. However, tests to confirm a stress trigger (e.g. early morning cortisol) are not useful. Experimental studies have shown increased expression of hypothalamic–pituitary–adrenal (HPA) hormone receptors e.g. corticotrophin-releasing hormone receptor 2, adrenocorticotropin and estrogen receptor 1 in lesional AA hair follicles. There was no consensus on the role of chronic stress as a disease trigger.

Consensus was achieved on the recording of Severity of Alopecia Tool (SALT) as a measure of disease activity both in clinical practice and clinical trials in children and adults. It was acknowledged that additional assessments (SSA, QoL) are required for the purpose of clinical trials. SALT has been validated in several AA studies for use in clinical trials/routine practice. Additional measures such as Alopecia Density and Extent (ALODEX) score have also been proposed.

There was agreement on the site of scalp biopsy. Of note, statement concerning the number of scalp biopsies - two or more biopsies (for horizontal and vertical sectioning), for the histological diagnosis of AA was discussed again at the face to face meeting following a specific request to revisit this was accepted. It was agreed that horizontal and vertical sectioning is important to confirm the histological diagnosis of AA, and that one single biopsy (sectioned horizontally and vertically) is usually sufficient to confirm the diagnosis of AA but that in some instances more than one biopsy may be needed.
Experts felt that clarity on this was essential as a question specifically on performing one single biopsy (sectioned horizontally and vertically) being sufficient for the diagnosis of AA, was not included in the questionnaire.

Consistent with current recommendations, diffuse AA may also necessitate a biopsy. Additional investigations to exclude AA mimickers, e.g. tinea capitis, is indicated only when there is clinical uncertainty. The expert group agreed that autoimmune screening investigations are not required in all AA patients, however, there was no consensus on testing specifically for vitamin D and thyroid disease. In patients with symptoms suggestive of co-existing auto-immune disease appropriate testing will still be required.

There was consensus agreement on worsening prognosis if AA persists beyond 5 years. Ikeda proposed 12 months and the current expert opinion is perhaps a reflection on treatment progress since Ikeda's historical observations in 1965.

Whilst disease duration of greater than 10 years may lead to irreversible hair loss, recommendations were not to exclude such patients from active treatment where available.

Nail disease, particularly pitting, was recognized as a poor prognostic finding with respect to developing a severe disease phenotype and affecting response to treatment. Trachyonychia may also act as a poor prognostic marker but there was no consensus on whether it affects response to treatment. Treatment success of trachyonychia has been reported.

ACE part II identified 66 non consensus questions. The majority (61) emerged following round 1 of the Delphi process and all with <33% consensus. This indicates wide divergence in opinion for these questions. The significant number of questions from etiopathogenesis and prognosis suggests that there is still much to learn and whilst data emerges and research informs, viewpoints may eventually merge.
There are potential limitations to consider. Firstly, whilst there was wide international participation and involvement of academic and community hair experts, there was low expert representation from Africa (n=1) South America (n=0) and Asia (n=3) and over representation from Europe (n=15) and North America (n=14). Secondly, the involvement of a hair scientist in the initial design of the questionnaire, to provide an additional perspective on AA pathogenesis, may have been beneficial. Thirdly, not all participants answered each question when presented the second or third time and 60%(30) attended the final face meeting in Stiges. Fourthly, as previously reported,\(^1\) time constraints to cast votes at the final face-to-face meeting, and influencer bias, as the meeting was not chaired by an independent, non-voting individual, are further possible limitations.

CONCLUSION

In summary, ACE Part II has provided insight into areas where current expert opinion is divided and where future research could potentially be directed, e.g. etiopathogenesis of AA. As we learn more about AA, the divergence may narrow, but in doing so we are hopeful that ACE Part II will provide a useful framework for dermatologists, health care providers and scientists alike, so that ultimately the greatest beneficiaries are our AA patients. Moreover, ACE has identified the need for an international AA registry, development of which will enable recording of comparable, robust, real-world data, to better inform on the prognostic significance of AA.
REFERENCES


FIGURE LEGENDS

Figure 1: The Delphi process in ACE

Figure 2: Summary of results from all Delphi rounds: ACE II

Table 1: Non-consensus outcomes for ACE II
Table 1: Non-consensus outcomes for ACE II

<table>
<thead>
<tr>
<th>Category</th>
<th>There was disagreement amongst the experts regarding the following statements</th>
</tr>
</thead>
<tbody>
<tr>
<td>Epidemiology</td>
<td>Ethnicity (race) influences the risk of developing AA. Climate/geographical latitude influences the risk of developing AA and influences the natural history/prognosis of AA.</td>
</tr>
</tbody>
</table>
| Etiopathogenesis    | Factors that were considered to increase the risk of developing AA include: a family history of atopy; vitamin D deficiency; viral illness and vaccination.  
Factors that were considered to increase the risk of developing AT/AU include: a family history of organ specific autoimmune disease/atopy; vitamin D deficiency and viral illness  
Factors that were considered to influence the natural history/prognosis of AA include: a family history of AA/organ specific autoimmune disease/atopy; vitamin D deficiency; pregnancy and viral illness.  
Factors that were considered to trigger initial disease and episodic relapse(s) include: chronic stress.  
Factors that were considered to influence response to treatment include: a family history of AA/organ specific autoimmune disease/atopy; a personal history of autoimmune disease/type 1 diabetes/myasthenia gravis/pernicious anaemia/psoriasis/lupus/rheumatoid arthritis/coeliac disease/atopy/asthma/allergic rhino-conjunctivitis/food allergy/allergic contact dermatitis; pregnancy; vitamin D deficiency and viral illness.  
Alopecia areata can be seasonal (regardless of geographic location) or cyclical (e.g. same month every year). |
| Clinical Features   | Signs that indicate disease activity (in addition to disease spread) include: telogen effluvium, scalp itch/tingling/dysesthesia and trichoscopic yellow dots.  
Outcome measures for clinical trials:  
• SALT is a sufficient measure of disease extent in adults and children  
• SALT + SSA is required to measure disease severity in children.  
Outcome measures for clinical practice:  
• SALT + SSA is required to measure disease severity in adults and children.  
• SALT + QoL (e.g. DLQI) is required to measure disease severity in adults and children.  
• SALT + SSA + QoL is required to measure disease severity in adults and children. |
| Diagnosis           | The optimal method of scalp biopsy is a single scalp biopsy sectioned horizontally or a single biopsy sectioned vertically.  
Trichograms are useful in the assessment of disease activity in AA. |
| Laboratory Evaluation | Routine screening bloods should be performed for: vitamin D deficiency and thyroid disease. |
| Prognosis and prognostic indicators | Active treatment early in the disease affects prognosis.  
Prognosis is worse when AA persists beyond 6 months/12 months.  
Hair loss can become irreversible when AA persists for <6 months/12 months/5 years/8years.  
Development of lesions of alopecia can be influenced by local factors.  
Trachyonychia alters response to treatment. |

Abbreviations: Alopecia Areata (AA); Alopecia areata Consensus of Experts (ACE); Dermatology Life Quality Index (DLQI); Quality of life (QoL); Severity of Alopecia Tool Score (SALT); Scalp Surface Area (SSA).
Figure 1 The Delphi process in ACE

- Literature search
- Questionnaire design
- Pilot
- Round 1 Delphi: Questionnaire round, 41 participants
- Round 2 Delphi: Questionnaire round, 39 participants
- Round 3 Delphi: Face to Face meeting, 30 participants
Figure 2 Summary of results from all Delphi rounds: ACE II

Round 1
148 questions
- 71 questions omitted
- ≤33% no consensus achieved N = 61
- ≥66% consensus achieved N = 10

Round 2
77 questions
- 47 questions omitted
- ≤33% no consensus achieved N = 0
- ≥66% consensus achieved N = 47

Round 3
32 questions
- 5 questions omitted
- ≤33% no consensus achieved N = 5 questions

Final Outcome
≥ 66% consensus achieved N = 82

2 questions were re-introduced
CAPSULE SUMMARY

1. This is the first large scale international consensus on the diagnosis and laboratory evaluation of AA.

2. The consensus document identifies potential areas where research may be directed.